Shares of MEDNAX Inc (NYSE:MD) have received an average recommendation of “Hold” from the sixteen brokerages that are presently covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $55.58.
Several research analysts recently commented on MD shares. ValuEngine lowered shares of MEDNAX from a “sell” rating to a “strong sell” rating in a research note on Wednesday, May 2nd. Citigroup reduced their price objective on shares of MEDNAX from $57.00 to $50.00 and set a “neutral” rating for the company in a research note on Friday, May 4th. Zacks Investment Research lowered shares of MEDNAX from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 21st. Jefferies Financial Group set a $58.00 price objective on shares of MEDNAX and gave the stock a “hold” rating in a research note on Thursday, March 15th. Finally, Credit Suisse Group reduced their price objective on shares of MEDNAX to $57.00 and set a “neutral” rating for the company in a research note on Monday, May 7th.
In other news, SVP Dominic J. Andreano sold 18,000 shares of the company’s stock in a transaction on Monday, June 11th. The shares were sold at an average price of $46.95, for a total value of $845,100.00. Following the sale, the senior vice president now directly owns 24,896 shares of the company’s stock, valued at approximately $1,168,867.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Vivian Lopez-Blanco sold 13,942 shares of the company’s stock in a transaction on Tuesday, June 12th. The shares were sold at an average price of $46.46, for a total transaction of $647,745.32. Following the completion of the sale, the chief financial officer now directly owns 100,590 shares in the company, valued at $4,673,411.40. The disclosure for this sale can be found here. In the last three months, insiders have sold 75,251 shares of company stock worth $3,462,384. 2.40% of the stock is owned by insiders.
Several hedge funds have recently added to or reduced their stakes in the company. Principal Financial Group Inc. boosted its holdings in shares of MEDNAX by 2.8% in the 1st quarter. Principal Financial Group Inc. now owns 408,927 shares of the company’s stock valued at $22,748,000 after acquiring an additional 11,154 shares during the last quarter. Summit Trail Advisors LLC boosted its holdings in shares of MEDNAX by 2,817.3% in the 1st quarter. Summit Trail Advisors LLC now owns 103,564 shares of the company’s stock valued at $104,000 after acquiring an additional 100,014 shares during the last quarter. Xact Kapitalforvaltning AB lifted its stake in shares of MEDNAX by 39.3% in the 1st quarter. Xact Kapitalforvaltning AB now owns 12,400 shares of the company’s stock valued at $690,000 after purchasing an additional 3,500 shares during the period. Royal Bank of Canada lifted its stake in shares of MEDNAX by 27.2% in the 1st quarter. Royal Bank of Canada now owns 40,603 shares of the company’s stock valued at $2,259,000 after purchasing an additional 8,692 shares during the period. Finally, Legal & General Group Plc lifted its stake in shares of MEDNAX by 16.4% in the 1st quarter. Legal & General Group Plc now owns 137,616 shares of the company’s stock valued at $7,655,000 after purchasing an additional 19,421 shares during the period. 97.02% of the stock is currently owned by institutional investors and hedge funds.
Shares of NYSE:MD traded up $0.09 during trading hours on Monday, hitting $43.44. The company’s stock had a trading volume of 569,328 shares, compared to its average volume of 879,199. MEDNAX has a 52 week low of $40.56 and a 52 week high of $63.04. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.74 and a current ratio of 1.74. The firm has a market cap of $4.09 billion, a P/E ratio of 13.79, a P/E/G ratio of 1.10 and a beta of 0.25.
MEDNAX (NYSE:MD) last posted its quarterly earnings results on Monday, April 30th. The company reported $0.89 EPS for the quarter, beating the consensus estimate of $0.82 by $0.07. MEDNAX had a net margin of 9.34% and a return on equity of 10.13%. The business had revenue of $901.90 million during the quarter, compared to analyst estimates of $903.75 million. During the same quarter in the previous year, the business posted $0.75 EPS. The company’s quarterly revenue was up 7.9% compared to the same quarter last year. research analysts predict that MEDNAX will post 3.94 EPS for the current fiscal year.
MEDNAX Company Profile
MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.